{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:07:30Z","timestamp":1780067250284,"version":"3.54.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There has been an increasing focus on the potential of cancer vaccines as a therapeutic oncological option, aiming to harness the immune system to recognize and eliminate malignant cells. Unlike traditional therapies, vaccines exploit tumour-associated antigens and neoantigens to generate durable, tumour-specific immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review provides a comprehensive overview of current vaccine strategies, their clinical applications, and implications for surgical oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical trials highlight promising results in high-mutational burden cancers such as melanoma, lung, and bladder cancer, as well as in traditionally \u2018cold\u2019 tumours like pancreatic cancer. Combination strategies, particularly with checkpoint inhibitors, have shown enhanced efficacy, exemplified by messenger RNA-4157\/V940 and autogene cevumeran in adjuvant settings. Off-the-shelf tumour-associated antigen vaccines offer scalability but face challenges of tolerance and limited specificity. Early data suggest vaccines may improve relapse-free survival and induce antigen spreading, broadening immune responses beyond the initial targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cancer vaccines are poised to complement surgery and systemic therapies, particularly in the perioperative window. Their integration into multimodal treatment strategies may redefine precision oncology, offering durable disease control and improved patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjsopen\/zrag041","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:41:47Z","timestamp":1774615307000},"source":"Crossref","is-referenced-by-count":0,"title":["Cancer vaccines: comprehensive review"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-0197","authenticated-orcid":false,"given":"Rachael E","family":"Clifford","sequence":"first","affiliation":[{"name":"Colorectal and Peritoneal Oncology Centre (CPOC), The Christie NHS Foundation Trust , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Manu","sequence":"additional","affiliation":[{"name":"The Liverpool Head and Neck Centre, The University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Arif","sequence":"additional","affiliation":[{"name":"Colorectal and Peritoneal Oncology Centre (CPOC), The Christie NHS Foundation Trust , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aggen","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Centre , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Bryan","sequence":"additional","affiliation":[{"name":"Centre for Immuno-Oncology, University of Oxford , Oxford ,","place":["UK"]},{"name":"Cancer Program, Broad Institute of MIT and Harvard , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Centre , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University College London Hospital , London ,","place":["UK"]},{"name":"Department of Medical Oncology, Mount Vernon Cancer Centre , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Church","sequence":"additional","affiliation":[{"name":"Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Corrie","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Savelyeva","sequence":"additional","affiliation":[{"name":"The Liverpool Head and Neck Centre, The University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ottensmeier","sequence":"additional","affiliation":[{"name":"The Liverpool Head and Neck Centre, The University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3593-2890","authenticated-orcid":false,"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield , Sheffield ,","place":["UK"]},{"name":"UK Vaccine Innovation Pathway, National Institute for Health and Care Research , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[{"name":"The Liverpool Head and Neck Centre, The University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026052910485867100_zrag041-B1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalised neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2026052910485867100_zrag041-B2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"2026052910485867100_zrag041-B3","doi-asserted-by":"crossref","first-page":"5825401","DOI":"10.1155\/2020\/5825401","article-title":"Cancer vaccines: toward the next breakthrough in cancer immunotherapy","volume":"2020","author":"Igarashi","year":"2020","journal-title":"J Immunol Res"},{"key":"2026052910485867100_zrag041-B4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: then and now","volume":"16","author":"Morse","year":"2021","journal-title":"Target Oncol"},{"key":"2026052910485867100_zrag041-B5","doi-asserted-by":"crossref","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front Immunol"},{"key":"2026052910485867100_zrag041-B6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","article-title":"The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer","volume":"130","author":"Ward","year":"2016","journal-title":"Adv Immunol"},{"key":"2026052910485867100_zrag041-B7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2026052910485867100_zrag041-B8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052910485867100_zrag041-B9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/bib\/bbz051","article-title":"A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction","volume":"21","author":"Mei","year":"2020","journal-title":"Brief Bioinform"},{"key":"2026052910485867100_zrag041-B10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1110\/ps.0239403","article-title":"Reliable prediction of T cell epitopes using neural networks with novel sequence representations","volume":"12","author":"Nielsen","year":"2003","journal-title":"Protein Sci"},{"key":"2026052910485867100_zrag041-B11","doi-asserted-by":"crossref","first-page":"e1000107","DOI":"10.1371\/journal.pcbi.1000107","article-title":"Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan","volume":"4","author":"Nielsen","year":"2008","journal-title":"PLoS Comput Biol"},{"key":"2026052910485867100_zrag041-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"2026052910485867100_zrag041-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"NetMHCpan, a method for MHC class I binding prediction beyond humans","volume":"61","author":"Hoof","year":"2009","journal-title":"Immunogenetics"},{"key":"2026052910485867100_zrag041-B14","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026052910485867100_zrag041-B15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cels.2018.05.014","article-title":"MHCflurry: open-source class I MHC binding affinity prediction","volume":"7","author":"O\u2019Donnell","year":"2018","journal-title":"Cell Syst"},{"key":"2026052910485867100_zrag041-B16","doi-asserted-by":"crossref","first-page":"S851","DOI":"10.1016\/j.annonc.2025.08.2155","article-title":"Why cancer vaccine models risk missing the patients who need them most","volume":"36","author":"Bryan","year":"2025","journal-title":"Ann Oncol"},{"key":"2026052910485867100_zrag041-B17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026052910485867100_zrag041-B18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"2026052910485867100_zrag041-B19","doi-asserted-by":"crossref","first-page":"e15877","DOI":"10.1371\/journal.pone.0015877","article-title":"Structural properties of MHC class II ligands, implications for the prediction of MHC class II epitopes","volume":"5","author":"J\u00f8rgensen","year":"2010","journal-title":"PLoS One"},{"key":"2026052910485867100_zrag041-B20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41467-021-21879-w","article-title":"DeepTCR is a deep learning framework for revealing sequence concepts within T cell repertoires","volume":"12","author":"Sidhom","year":"2021","journal-title":"Nat Commun"},{"key":"2026052910485867100_zrag041-B21","doi-asserted-by":"crossref","first-page":"640725","DOI":"10.3389\/fimmu.2021.640725","article-title":"TCRMatch: predicting T-cell receptor specificity based on sequence similarity to previously characterized receptors","volume":"12","author":"Chronister","year":"2021","journal-title":"Front Immunol"},{"key":"2026052910485867100_zrag041-B22","doi-asserted-by":"crossref","first-page":"i237","DOI":"10.1093\/bioinformatics\/btab294","article-title":"TITAN: T cell receptor specificity prediction with bimodal attention networks","volume":"37","author":"Weber","year":"2021","journal-title":"Bioinformatics"},{"key":"2026052910485867100_zrag041-B23","doi-asserted-by":"crossref","first-page":"e0324011","DOI":"10.1371\/journal.pone.0324011","article-title":"Assessing the generalization capabilities of TCR binding predictors via peptide distance analysis","volume":"20","author":"Castorina","year":"2025","journal-title":"PLoS One"},{"key":"2026052910485867100_zrag041-B24","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumour mutation burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"2026052910485867100_zrag041-B25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"\u0141uksza","year":"2022","journal-title":"Nature"},{"key":"2026052910485867100_zrag041-B26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"2026052910485867100_zrag041-B27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"2026052910485867100_zrag041-B28","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"key":"2026052910485867100_zrag041-B29","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","journal-title":"The Lancet"},{"key":"2026052910485867100_zrag041-B30","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","journal-title":"The Lancet"},{"key":"2026052910485867100_zrag041-B31","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.2008.20.2853","article-title":"Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck","volume":"27","author":"Lassen","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"key":"2026052910485867100_zrag041-B33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"2026052910485867100_zrag041-B34","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2005.04.6136","article-title":"High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma","volume":"24","author":"Licitra","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B36","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/cells9092103","article-title":"HNSCC: tumour antigens and their targeting by immunotherapy","volume":"9","author":"von Witzleben","year":"2020","journal-title":"Cells"},{"key":"2026052910485867100_zrag041-B37","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-15-2507","article-title":"Targeting carcinoembryonic antigen with DNA vaccination: on-target adverse events link with immunologic and clinical outcomes","volume":"22","author":"McCann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026052910485867100_zrag041-B38","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00262-012-1270-0","article-title":"DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T cell responses and increases PSA doubling time","volume":"61","author":"Chudley","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2026052910485867100_zrag041-B39","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/hum.2009.067","article-title":"DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer","volume":"20","author":"Low","year":"2009","journal-title":"Hum Gene Ther"},{"key":"2026052910485867100_zrag041-B40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc2326","article-title":"DNA vaccines: precision tools for activating effective immunity against cancer","volume":"8","author":"Rice","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2026052910485867100_zrag041-B41","doi-asserted-by":"crossref","first-page":"e003821","DOI":"10.1136\/jitc-2021-003821","article-title":"Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer","volume":"10","author":"McCann","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026052910485867100_zrag041-B42","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1200\/JCO.2025.43.16_suppl.6016","article-title":"Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts)","volume":"43","author":"Tourneau","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B43","doi-asserted-by":"crossref","first-page":"S680","DOI":"10.1016\/j.annonc.2024.08.1058","article-title":"999MO HARE-40: a phase I\/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma","volume":"35","author":"Ottensmeier","year":"2024","journal-title":"Ann Oncol"},{"key":"2026052910485867100_zrag041-B44","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1464-410X.2010.09933.x","article-title":"A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin","volume":"108","author":"Matsumoto","year":"2011","journal-title":"BJU Int"},{"key":"2026052910485867100_zrag041-B45","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/cas.13404","article-title":"Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma","volume":"108","author":"Suekane","year":"2017","journal-title":"Cancer Sci"},{"key":"2026052910485867100_zrag041-B46","doi-asserted-by":"crossref","first-page":"LBA9503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","article-title":"Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial","volume":"41","author":"Khattak","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/1078-0432.CCR-15-1265","article-title":"An open-label, randomized phase II trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum-based chemotherapy","volume":"22","author":"Noguchi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026052910485867100_zrag041-B48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"2026052910485867100_zrag041-B49","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nat Cancer"},{"key":"2026052910485867100_zrag041-B50","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/JCO.2021.39.15_suppl.4522","article-title":"Phase I\/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"39","author":"Matsumoto","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2026052910485867100_zrag041-B52","author":"ClinicalTrials.gov"},{"key":"2026052910485867100_zrag041-B53","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","article-title":"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors","volume":"37","author":"Burris","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B54","first-page":"A477","article-title":"798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update","volume":"8","author":"Bauman","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052910485867100_zrag041-B55","doi-asserted-by":"crossref","first-page":"TPS893","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS893","article-title":"Phase 1\/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC)","volume":"43","author":"Sonpavde","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B56","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"2026052910485867100_zrag041-B57","doi-asserted-by":"crossref","first-page":"TPS9616","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9616","article-title":"INTerpath-001: pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II\u2013IV melanoma","volume":"42","author":"Weber","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B58","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1200\/JCO.2024.42.16_suppl.9535","article-title":"A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial","volume":"42","author":"Shaw","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026052910485867100_zrag041-B59","doi-asserted-by":"crossref","first-page":"LB214","DOI":"10.1158\/1538-7445.AM2025-LB214","article-title":"A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial","volume":"85","author":"Shaw","year":"2025","journal-title":"Cancer Res"},{"key":"2026052910485867100_zrag041-B60","author":"Koronka","year":"2025"},{"key":"2026052910485867100_zrag041-B61","author":"BioNTech"},{"key":"2026052910485867100_zrag041-B62","author":"Ascierto PA"},{"key":"2026052910485867100_zrag041-B63","author":"ClinicalTrials.gov"},{"key":"2026052910485867100_zrag041-B64","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"2026052910485867100_zrag041-B65","author":"ClinicalTrials.gov"},{"key":"2026052910485867100_zrag041-B66","author":"ClinicalTrials.gov"},{"key":"2026052910485867100_zrag041-B67","author":"ClinicalTrials.gov"},{"key":"2026052910485867100_zrag041-B68","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"2026052910485867100_zrag041-B69","author":"ClinicalTrials.gov"},{"key":"2026052910485867100_zrag041-B70","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat Med"},{"key":"2026052910485867100_zrag041-B71","author":"ClinicalTrials.gov"},{"key":"2026052910485867100_zrag041-B72","author":"Hassel JC"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/10\/3\/zrag041\/68431684\/zrag041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/10\/3\/zrag041\/68431684\/zrag041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:49:10Z","timestamp":1780066150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zrag041\/8697997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zrag041","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,12]]},"article-number":"zrag041"}}